Sentence examples for developing a potent and from inspiring English sources

We use Pittsburgh compound B to illustrate some of the critical steps in developing a potent and selective Aβ PET imaging agent.

(1′S*,2′S* --6-Nor-2′,3′-dihydro-4′-deoxo-ABA (2) was designed and synthesized as a candidate lead compound for developing a potent and specific inhibitor of ABA 8′-hydroxylase.

Several researchers attempted to identify mechanisms responsible for asphaltenes precipitation and deposition as well as to develop a potent and reliable representative model to quantitatively and qualitatively estimate the extent of asphaltene precipitation and deposition.

Nevertheless further investigations are required to find the active component of the extract and to confirm the possible mechanism of action for developing a potent medicinal agent.

Developing a potent strategic plan is not easy.

We have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys481.

In this letter we describe how we modified substitution around this pharmacophore to develop a potent, selective and orally active renin inhibitor.

113 Their search was initiated by a high-throughput screen of their compound library followed by optimization of their lead structure to develop a potent, selective, and orally-available compound, (2E -3- 4- [2,4-bis trifluoromethyl benzyl] oxy)-3-methoxyphenyl)-2E -3- 4- [2,4-bis trifluoromethyl benzyladiazol-2E -3- 4- [2,4-bis trifluoromethyl benzyl

By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k).

Using a structure-based design, we developed a potent SPR inhibitor and show that it reduces pain hypersensitivity effectively with a concomitant decrease in BH4 levels in target tissues, acting both on sensory neurons and macrophages, with no development of tolerance or adverse effects.

Here, we utilized the helix12 (H12 -folding inH12 -foldingothesinhibitionbination withypothesisinusly determined X-ray combinationucture of PPARγ agonist MEKT-21 (6) complexed with the PPARγ ligand-binding dourin, to design and developreviously phenylalkynyl amideterminedARγ antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6.